Roles of Interstitial Albumin in the Subcutaneous Delivery of Therapeutic Peptides
Advanced Science · 09.11.2026
DOI: 10.1002/advs.78760 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 09.11.2026. Verfasst von David Juriga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Physical Chemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Biomedicinskt Centrum BMC, Uppsala, Sw…. Die Arbeit nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Faculty of Medicine and Pharmacy at Uppsala University and Vinnova, Swedish Cancer Society, Swedish Research Council.
Abstract (Originalsprache)
Subcutaneous administration of biotherapeutics is increasingly favored for better safety profile, improved stability, and patient compliance compared with intravenous administration. Despite these advantages, the roles of extracellular matrix (ECM) components and interstitial proteins, particularly albumin, in the mechanisms governing therapeutic pharmacokinetics and bioavailability remain poorly understood. We present a versatile and customizable hydrogel platform resembling native ECM in composition, charge density, and microstructure, enabling systematic investigation of transport mechanisms in the subcutaneous space. Using this platform, we studied peptides with different net charges and albumin affinities. Based on results from confocal microscopy combined with measurements of diffusivities by means of FRAP, we propose a role for albumin beyond that of a transport vehicle for drugs. We show that reversible peptide‐albumin binding can both remove peptides bound to the ECM biopolymers and modulate peptide diffusivity and distribution, as albumin was found to have an affinity for matrix glycosaminoglycans. For cationic peptides, albumin had a major influence on diffusivity and distribution in the matrix, with more pronounced effects over time in vitro. These findings, complemented by exploratory in vivo observations in a limited cohort, highlight realistic ECM structure and albumin inclusion as key considerations for predictive in vitro subcutaneous models.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pharmaceutical Physical Chemistry, Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Biomedicinskt Centrum BMC, Uppsala, Sweden.
- Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Biomedicinskt Centrum BMC, Uppsala, Sweden.
- Theranostics Group, Department of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, Biomedicinskt Centrum BMC, Uppsala, Sweden.
ORCID-Profile: David Juriga, Anton Norberg, Esther Olaniran Håkansson, Jeroen W van den Heuvel, Johan Gråsjö, Luke R Odell, Anna Orlova, Per Hansson
Förderung
- Faculty of Medicine and Pharmacy at Uppsala University and Vinnova
- Swedish Cancer Society
- Swedish Research Council
- Cancerfonden
- Vetenskapsrådet
Zitieren
APA
Juriga, D., Norberg, A., Håkansson, E. O., W van den Heuvel, J., Gråsjö, J., Odell, L. R., Orlova, A., & Hansson, P. (2026). Roles of Interstitial Albumin in the Subcutaneous Delivery of Therapeutic Peptides. Advanced Science. https://doi.org/10.1002/advs.78760
Vancouver
Juriga D, Norberg A, Håkansson EO, W van den Heuvel J, Gråsjö J, Odell LR, et al. Roles of Interstitial Albumin in the Subcutaneous Delivery of Therapeutic Peptides. Advanced Science. 2026. doi:10.1002/advs.78760
BibTeX
@article{Juriga2026,
author = {Juriga, David and Norberg, Anton and Håkansson, Esther Olaniran and W van den Heuvel, Jeroen and Gråsjö, Johan and Odell, Luke R and Orlova, Anna and Hansson, Per},
title = {Roles of Interstitial Albumin in the Subcutaneous Delivery of Therapeutic Peptides},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78760}
}
EUVIMED